Download Robert I Griffiths CV - Nuffield Department of Primary Care

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Robert Ian Griffiths MS, ScD
533 Calderwood Hill Road
Craftsbury, Vermont, 05826, USA
email: [email protected]
Citizenships: United States/United Kingdom
Research Interests and Expertise
For more than 25 years my research has focused on identifying demographic, clinical, and economic factors that
influence the use, outcomes, and costs of new medical technology in routine clinical practice. Most recently I
have been involved in several projects to evaluate the comparative effectiveness and costs of cancer treatment
in elderly patients. I am particularly interested in how co-morbidity and patterns of health system contact prior
to cancer diagnosis impact treatment decisions and outcomes, with the goal of improving the effectiveness,
efficiency, and equity of care in these patients.
My main area of expertise is epidemiologic and economic studies using large data sets such as the National
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) cancer registry linked to Medicare health
insurance claims, and the United States Renal Data System. Also, I have designed specialized databases at
academic medical centers and other health care institutions in the United States and Europe to address a wide
spectrum of clinical and economic research questions. In this capacity, I have developed broad expertise in
research design, epidemiology, health economics, and biostatistics, concentrating on approaches that address
the limitations of observational data for medical technology and practice assessment, including confounding and
censoring.
I am also increasingly interested in using network analysis to understand the structure of health care delivery
systems, how they behave under various policy and financial constraints, and how they adapt to treat patients
with multiple chronic conditions.
Relevant Professional Experience
2013 →
Senior Research Fellow
Nuffield Department of Primary Care Health Sciences
University of Oxford
Oxford, UK
Tel: +44(0)1865 617855
https://www.phc.ox.ac.uk/team/researchers/robert-griffiths
I am joint lead investigator on a 32-month grant from Cancer Research UK that will entail using
the English Clinical Practice Research Datalink (CPRD) to study the quality and outcomes of care
for comorbid conditions in patients diagnosed with breast, colorectal, or prostate cancer.
Cancer Research UK: 16609
Project Title: Quality and outcomes of care for chronic conditions in older patients diagnosed
with breast, colorectal, or prostate cancer compared to non-cancer controls: An observational
study using the Clinical Practice Research Datalink.
1
1995 →
Faculty Part Time, Division of General Internal Medicine
The Johns Hopkins University School of Medicine
http://www.hopkinsmedicine.org/gim/faculty/p-t_alpha.html
I collaborate on an ad hoc basis with other faculty and staff at the University to conduct
comparative effectiveness and health services research.
2008 -2013
Vice President, Outcomes Insights, Inc.
Westlake Village, California
2000-2008
Founder, Health Economics Consulting
Craftsbury, Vermont
I was responsible for designing and implementing research to evaluate the clinical and economic
outcomes of a vaccine for preventing Staphylococcus aureus bloodstream infection resulting
from renal dialysis. This included assembling and coordinating teams of researchers from
Europe and the United States, building a computerized decision-analysis model for simulating
the cost-effectiveness of vaccination, designing and coordinating the implementation of
observational studies throughout Europe and the United States, and participating in writing
manuscripts.
1995-1999
Vice President, Covance Health Economics and Outcomes Services, Inc.
Washington, District of Columbia
1993-1994
Assistant Professor of Medicine
The Johns Hopkins University School of Medicine
1993-1994
Assistant Professor of Health Policy and Management
The Johns Hopkins University School of Hygiene and Public Health
1989-1993
Research Assistant, Program for Medical Technology and Practice Assessment
The Johns Hopkins University School of Medicine
Education
2012 →
Doctor of Philosophy (DPhil), Evidence-Based Health Care
Department of Primary Care Health Sciences
University of Oxford (Balliol College)
Oxford, United Kingdom
1989-1993
Doctor of Science (ScD), Health Policy and Management (concentration in health finance)
School of Hygiene and Public Health
The Johns Hopkins University
Baltimore, Maryland
2
Doctoral Dissertation: The Comparative Performance of For-Profit and Not-for-Profit
Independent Renal Dialysis Facilities. Johns Hopkins University, 1993.
Related publication: Griffiths RI, Powe NR, Gaskin DJ, Anderson GF, de Lissovoy GV, Whelton PK.
The Production of Dialysis by For-Profit versus Not-For-Profit Freestanding Renal Dialysis
Facilities. HSR: Health Services Research 1994;29(4):473-487.
1988-1989
Doctor of Philosophy (candidate), Urban Affairs
College of Urban Affairs and Public Policy
University of Delaware
Newark, Delaware
1986-1988
Master of Science (MS), Science and Technology Studies
Virginia Polytechnic Institute and State University
Blacksburg, Virginia
Master’s Thesis: Industrial Drug Development: Application of the Theoretical Framework of
Abernathy, Clark, and Kantrow (1983) in an Analysis of Factors Which Determine Productivity.
1979-1983
Bachelor of Arts, Geography
College of Arts and Sciences
University of Delaware
Doctoral Student Honor
1991
The John P. Young Memorial Prize (top student paper in health finance and economics)
School of Hygiene and Public Health
The Johns Hopkins University
3
Journal Articles
Griffiths RI, Gleeson ML, Valderas JM, Danese MD. Undiagnosed Comorbidity in Older Women with Breast
Cancer: Incidence, Risk Factors, and Outcomes. (International Journal of Breast Cancer. In Press).
Griffiths RI, Lindquist KJ, O’Malley CD, Gleeson ML, Duryea JL, Valderas JM, Danese MD. Undiagnosed Diabetes
in Breast, Colorectal, Lung, and Prostate Cancer: Incidence and Risk Factors. (ISRN Oncology. In Press).
Griffiths RI, O’Malley CD, Herbert RJ, Danese MD. Misclassification of Incident Conditions Using Claims
Data: Impact of Varying the Period Used to Exclude Pre-Existing Disease. BMC Medical Research
Methodology, 2013;13:32. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602098/pdf/1471-2288-13-32.pdf
Chia V, Danese M, O’Malley C, Lindquist K, Gleeson M, Kelsh M, Griffiths RI. Prevalence and Incidence of
Comorbidities in Elderly Women with Ovarian Cancer. Gynecologic Oncology, 2013;129(2):346-52.
Griffiths RI, Danese MD, Gleeson ML, Valderas JM. Epidemiology and Outcomes of Previously Undiagnosed
Diabetes in Older Women Diagnosed With Breast Cancer: An Observational Cohort Study Based on SEERMedicare. BMC Cancer, 2012;12:613. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575284/pdf/1471-240712-613.pdf
Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on Medical Cost, Cumulative Survival, and CostEffectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma (FL) in Elderly
Patients: An Observational Cohort Study Based on SEER-Medicare. Journal of Cancer Epidemiology,
2012, Article ID 978391, 13 pages.
Griffiths RI, Gleeson ML, Danese MD, O’Hagan A. Inverse Probability Weighted Least Squares
Regression in the Analysis of Time-Censored Cost Data: An Evaluation of the Approach Using SEERMedicare. Value in Health, 2012;15:656-663.
Griffiths RI, Gleeson ML, Mikhael J, Dreyling M, Danese MD. Comparative Effectiveness and Cost of
Adding Rituximab to First-Line Chemotherapy for Elderly Patients Diagnosed with Diffuse Large B-Cell
Lymphoma. Cancer, 2012;118(24):6079-6088.
Danese MD, Lindquist K, Doan J, Lalla D, Brammer M, Griffiths RI. Effect of Central Nervous System Metastases
on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast
Cancer. Journal of Cancer Epidemiology, 2012, Article ID 819210, 9 pages.
Griffiths RI, Newsome BB, Leung G, Block GA, Herbert RJ, Danese MD. Impact of Hemodialysis Catheter Blood
Flow < 300ml/min (Catheter Dysfunction) on Dialysis and Other Medical Services: An Observational Cohort
Study. International Journal of Nephrology, 2012;2012:673954. Epub 2012 Feb 13.
Griffiths RI, Barron RL, Gleeson ML, Danese MD, O’Hagan A, Chia VM, Legg JC, Lyman GH. GranulocyteColony Stimulating Factor (G-CSF) Use and Medical Costs after Initial Adjuvant Chemotherapy in Older
Patients with Early-Stage Breast Cancer (ESBC). PharmacoEconomics, 2012;30(2):103-118.
4
Griffiths RI, Newsome BB, Block GA, Herbert RJ, Danese MD. Patterns of Hemodialysis Catheter
Dysfunction Defined According to National Kidney Foundation Guidelines as Blood Flow < 300 ml/min.
International Journal of Nephrology, 2011;2011:891529. Epub 2011 Dec 8.
Danese MD, O’Malley C, Lindquist K, Gleeson M, Griffiths RI. An Observational Study of the Prevalence
and Incidence of Comorbid Conditions in Older Women with Breast Cancer. Ann Oncol, 2011 Oct 29.
[Epub ahead of print]
Griffiths R, Lalla D, Herbert R, Doan J, Brammer M, Danese M. Infused Therapy and Survival in Older
Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Cancer Investigation,
2011;29(9):573-584.
Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M. Addition of Rituximab to Chemotherapy Alone
as First-Line Therapy Improves Overall Survival in Elderly Patients with Mantle Cell Lymphoma. Blood,
2011;118(18):4808-4816.
Danese MD, Griffiths RI, Gleeson M, Satram-Hoang S, Knopf K, Mikhael J, Reyes C. An Observational
Study of Outcomes After Initial Infused Therapy in Medicare Patients Diagnosed with Chronic
Lymphocytic Leukemia. Blood, 2011;117(13):3505-3513.
Lindquist KJ, Danese MD, Mikhael J, Knopf KB, Griffiths RI. Health Care Utilization and Mortality Among
Elderly Patients with Myelodysplastic Syndromes. Ann Oncol, 2011;22(5):1181-1188.
Griffiths R, Gleeson M, Knopf K, Danese M. Racial Differences in Treatment and Survival in Older
Patients with Diffuse Large B-Cell Lymphoma (DLBCL). BMC Cancer, 2010; 10:625-639.
Griffiths R, Gleeson M, Reyes C, Knopf K, Danese M. Survival in Elderly Follicular Lymphoma Patients
who Receive Frontline Chemo-Immunotherapy. Am J Hematology, 2010;85(12):963-967.
Li Y, Friedman JY, O'Neal BF, Hohenboken MJ, Griffiths RI, Stryjewski ME, Middleton JP, Schulman KA,
Inrig JK, Fowler VG Jr, Reed SD. Outcomes of Staphylococcus Aureus Infection in HemodialysisDependent Patients. Clin J Am Soc Nephrol, 2009; Feb;4(2):428-34. Epub 2008 Dec 31.
Lalani T, Chu VH, Grussemeyer CA, Reed SD, Bolognesi MP, Friedman JY, Griffiths RI, Crosslin DR,
Kanafani ZA, Kaye KS, Ralph Corey G, Fowler VG Jr. Clinical Outcomes and Costs Among Patients with
Staphylococcus Aureus Bacteremia and Orthopedic Device Infections. Scand J Infect Dis, 2008;40(1112):973-7.
Doan QV, Gleeson M, Kim J, Borker R, Griffiths R, Dubois RW. Economic Burden of Cardiovascular
Events and Fractures Among Patients with End-Stage Renal Disease. Current Medical Research and
Opinion, 2007: 23 (7);1561-1569.
Danese MD, Liu Z, Griffiths RI, Dylan M, Yu H-T, Dubois R, Nissenson AR. Catheter Use Is High Even
Among Hemodialysis Patients With a Fistula or Graft. Kidney International, 2006:70;1482-1485.
5
Stovsky MD, Griffiths RI, Duff S. A Clinical Outcomes and Cost Analysis Comparing Photoselective
Vaporization of the Prostate to Alternative Minimally Invasive Therapies and TURP for the Treatment of
Benign Prostatic Hyperplasia. J Urol, 2006:176;1500-1506.
Nissenson AR, Dylan ML, Griffiths RI, Yu H-T, Dubois RW. Septicemia in Patients with ESRD is Associated
with Decreased Hematocrit and Increased Use of Erythropoietin. Clin J Am Soc Nephrol, 2006;1:505-510.
Danese M, Griffiths RI, Dylan M, Yu H-T, Dubois R, Nissenson A. Mortality Differences Among Organisms
Causing Septicemia in Hemodialysis Patients. Hemodialysis International, 2006:Jan;10(1):56-62.
Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and
pelvic fractures among patients on dialysis. Am J Kidney Dis, 2006: Jan;47(1):149-56.
Chu VH, Crosslin DR, Friedman JY, Reed SD, Cabell CH, Griffiths RI, Masselink LE, Kaye KS, Corey GR,
Reller LB, Stryjewski ME, Schulman KA, Fowler VG. Staphylococcus Aureus Bacteremia in Patients with
Prosthetic Devices: Costs and Outcomes. American Journal of Medicine, 2005;118:1416.e19-1416.e24.
Nissenson A, Dylan M, Griffiths R, Yu H-T, Dean B, Danese M, Dubois R. Clinical and Economic Outcomes
of Staphylococcus Aureus Septicemia in End-Stage Renal Disease Patients Receiving Hemodialysis. Am J
Kidney Dis, 2005;46(2):301-308.
Reed SD, Friedman JY, Engemann JJ, Griffiths RI, Anstrom KA, Kaye KS, Stryjewski ME, Szczech LA, Reller
LB, Corey GR, Schulman KA, Fowler Jr VG. Resource Utilization, Costs, and Mortality are Higher Among
Hemodialysis-Dependent Patients with Bacteremia Caused by Methicillin-Resistant Staphylococcus
Aureus Compared to Methicillin-Susceptible Staphylococcus aureus. Infection Control and Hospital
Epidemiology, 2005;26(2):175-183.
Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, Stryjewski ME, Reller LB, Schulman
KA, Corey GR, Fowler Jr. VG. Clinical Outcomes and Costs Due to Staphylococcus Aureus Bacteremia
Among Patients on Chronic Hemodialysis. Infection Control and Hospital Epidemiology, 2005;26:534539.
Griffiths RI, Slurzberg JEF. Cost effectiveness of PROSORBA® Column Therapy for Rheumatoid Arthritis:
A Framework for Analysis. Therapeutic Apheresis 2001;5(2):105-110.
Griffiths RI, Bar-Din M, Sullivan EM, Herbert RJ, Yelin EH. Patterns of DMARD Use, Medical Resource
Consumption, and Cost Among Rheumatoid Arthritis Patients. Therapeutic Apheresis 2001;5(2).
Griffiths RI, Rabeneck L, Guzman G, Cromwell DM, Strauss MJ, Robinson JW, Winston B, Li T, Graham
DY. Costs of Managing Helicobacter Pylori-Infected Ulcer Patients after Initial Therapy. Helicobacter
2001;6(1):66-76.
Griffiths RI, Bar-Din M, MacLean C, Sullivan EM, Herbert RJ, Yelin EH. Medical Resource Use and Costs
Among Rheumatoid Arthritis Patients Receiving Disease Modifying Antirheumatic Drug Therapy.
Arthritis Care and Research 2000; 1364:213-226.
6
Sullivan EM, Griffiths RI, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH. One-Year Costs of
Second-Line Therapies for Depression. Journal of Clinical Psychiatry 2000:61:290-298.
Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical Costs of Treating Venous
Stasis Ulcers: Evidence from a Retrospective Cohort Study. Vascular Medicine 1999;4:1-7.
Griffiths RI, Sullivan EM, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH. Medical Resource Use
and Cost of Venlafaxine or Tricyclic Antidepressant Therapy Following Selective Serotonin Reuptake
Inhibitor Therapy for Depression. PharmacoEconomics 1999 May;15(5):495-505.
Griffiths RI, Schrammel PN, Morris GL, Wills SH, Labiner DM, Strauss MJ. Payer Costs of Patients
Diagnosed with Epilepsy. Epilepsia 1999;40(3):351-358.
Griffiths RI, Hyman CL, McFarlane SI, Saurina GR, Anderson JE, O’Brien T, Popper C, McGrath MM,
Herbert RJ, Sierra MF. Medical Resource Use for Suspected Tuberculosis in a New York City Hospital.
Infection Control and Hospital Epidemiology 1998;19(10):747-753.
Snyder C, Schrammel P, Griffiths CB, Griffiths RI. Prostate Cancer Screening in the Workplace: Employer
Costs. AAOHN Journal 1998;46(8):379-384.
Schrammel P, Griffiths RI, Griffiths CB. A Workplace Breast Cancer Screening Program: Costs and
Components. AAOHN Journal 1998;46(11):523-529.
Griffiths RI, Bleecker GC, Jabs DA, Dieterich DT, Coleson L, Winters D, Wolitz R, Steinberg EP.
Pharmacoeconomic Analysis of 3 Treatment Strategies for Cytomegalovirus Retinitis in Patients with
AIDS. PharmacoEconomics 1998;13(4):461-474.
Griffiths RI, O’Brien TW, Eisenberg P, Ferriter J, Popper C, Tsai WW, Robinson JW. Impact of Performing
STAT Complete Blood Counts at the Point of Care in an Ambulatory Care Setting. The Talbert Journal of
Health Care Winter 1996/1997.
Dorsey JH, Holtz PM, Griffiths RI, McGrath MM, Steinberg EP. Costs and Charges Associated with Three
Alternative Techniques of Hysterectomy. N Engl J Med 1996;335:476-482.
Moore RD, Chaulk CP, Griffiths RI, Cavalcante S, Chaisson RE. Cost-Effectiveness of Directly Observed
Versus Self-Administered Therapy for Tuberculosis. American Journal of Respiratory and Critical Care
Medicine 1996;154:1013-1019.
Griffiths RI, McGrath MM, Vogel VG. Economic Savings and Costs of Periodic Mammographic Screening
in the Workplace. Oncology 1996;10:285-293.
Powe NR, Griffiths RI. The Clinical-Economic Trial: Promise, Problems, and Challenges. Controlled
Clinical Trials 1995;16:377-394.Griffiths RI, Anderson GF, Powe NR, Oliveras E, Herbert RJ, Grant CC,
Davidson BL. Economic Impact of Immunization Against Rotavirus Gastroenteritis: Evidence From a
Clinical Trial. Archives of Pediatrics and Adolescent Medicine 1995;149:407-414.
7
Powe NR, Griffiths RI. Clinical-Economic Trials Background Paper 5. In: Tools for Evaluating Health
Technologies: Five Background Papers. Washington, DC: U.S. Government Printing Office, February
1995. BP-H-142.
Griffiths RI, Griffiths CB, Powe NR. Simulated Lifetime Costs of Three Types of Employer-Based Periodic,
Breast Cancer Screening Programs for Working-Age Women. American Journal of Health Promotion
1994;9(2):137-146.
Griffiths RI, Powe NR, Gaskin DJ, Anderson GF, de Lissovoy GV, Whelton PK. The Production of Dialysis
by For-Profit versus Not-For-Profit Freestanding Renal Dialysis Facilities. HSR: Health Services Research
1994;29(4):473-487.
Bass EB, Steinberg EP, Pitt HA, Griffiths RI, Lillemoe KD, Saba GP, Johns C. Comparison of the Rating
Scale and Standard Gamble Approaches in Measuring Patient Utility Values for Outcomes of Gallstone
Disease. Medical Decision Making 1994; 14:307-314.
Griffiths RI, Powe NR, Greer JW, de Lissovoy G, Anderson GF, Whelton PK, Watson AJ, Eggers PW. A
Review of the First Year of Medicare Coverage of Erythropoietin. Health Care Financing Review
1994;15(3):83-102.
de Lissovoy G, Powe NR, Griffiths RI, Watson AJ, Anderson GF, Greer JW, Herbert RJ, Eggers P, Milam R,
Whelton PK. The Relationship of Provider Organizational Status and Erythropoietin Dosing in End Stage
Renal Disease Patients. Medical Care 1994;32(2):130-140.
Powe NR, Griffiths RI, Watson AJ, Anderson GF, de Lissovoy G, Greer JW, Herbert RJ, Milam RA, Whelton
PK. Effect of Recombinant Erythropoietin on Hospital Admissions, Readmissions, Length of Stay, and
Costs of Dialysis Patients. J Am Soc Nephrol 1994; 4:1455-1465.
Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR. Efficacy of Immune
Globulin in Preventing Complications of Bone Marrow Transplantation: A Meta-Analysis. Bone Marrow
Transplantation 1993;12(3):273-282.
Griffiths RI, Bass EB, Powe NR, Anderson GF, Goodman SN, Wingard JR. Factors Influencing Third Party
Payer Costs for Allogeneic BMT. Bone Marrow Transplantation 1993;12:43-48.
Powe NR, Griffiths RI, Anderson GF, de Lissovoy G, Watson AJ, Greer JW, Herbert RJ, Whelton PK.
Medicare Payment Policy and Recombinant Erythropoietin Prescribing for Dialysis Patients. American
Journal of Kidney Diseases 1993;22:557-567.
Bass EB, Griffiths RI. Cost Effectiveness of Laparoscopic Surgery: From Whose Perspective? Journal of
Laparoendoscopic Surgery 1993;3(3):203-204.
Powe NR, Griffiths RI, Bass EB. Cost Implications to Medicare of Recombinant Erythropoietin Therapy
for the Anemia of End-Stage Renal Disease. J Am Soc Nephrol 1993;3(10):1660-1671.
8
Powe NR, Griffiths RI, Greer JW, Watson AJ, Anderson GF, de Lissovoy G, Herbert RJ, Eggers PW, Milam
R, Whelton PK. Early Dosing Practices and Effectiveness of Recombinant Human Erythropoietin. Kidney
Int 1993;43:1125-1133.
Powe NR, Griffiths RI, de Lissovoy G, Anderson GF, Watson AJ, Greer JW, Herbert RJ, Eggers P, Milam R,
Whelton PK. Access to Recombinant Erythropoietin by Medicare-Entitled Dialysis Patients in the First
Year After FDA Approval. JAMA 1992;268(11): 1434-1440.
Griffiths RI. Was There a Crisis Before the Compernican Revolution? A Reappraisal of Gingerich’s
Criticisms of Kuhn. PSA: Proceedings of the Biennial Meeting of the Philosophy of Science Association,
vol. 1988, Volume One: Contributed Papers (1988), pp. 127-132.
9
Conference Abstracts and Workshops
Danese M, Griffiths R, Gleeson M. et al. Patterns of Care, Survival, and Costs of Second-Line Treatment in
Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology, Annual
Meeting. New Orleans, LA. December 7-10, 2013.
Danese M, Cetin K, Katz A, Kelsh M, Gleeson M, Griffiths R. Patterns of Care in Medicare Beneficiaries
Diagnosed with Acute Lymphoblastic Leukemia. American Society of Hematology, Annual Meeting. New
Orleans, LA. December 7-10, 2013.
O’Malley CD, Griffiths RI, Herbert RJ, Danese MD. Impact of Look-Back Periods on Misclassification. American
College of Epidemiology, 2012. Chicago, USA.
Griffiths RI, Gleeson M, Paragamian V, Danese MD, Brenner RM. Epidemiology and Outcomes of Acute Kidney
Injury after Cardiac Surgery. American Society of Nephrology, 2011. Philadelphia, USA.
O’Hagan A, Gleeson ML, Danese MD, Griffiths RI. Inverse Probability-Weighted Least Squares Regression For
Estimating Population Mean Costs of Alternative Interventions Using Observational Data. ISPOR 16th Annual
Meeting, 2011. Baltimore, USA.
Griffiths RI, Gleeson ML, Mikhael JR, Danese MD. Long-Term Direct Medical Costs in Patients Diagnosed with
Follicular Lymphoma Who Receive Frontline Chemotherapy With Versus Without Rituximab – A SEER-Medicare
Analysis. ISPOR 16th Annual Meeting, 2011. Baltimore, USA.
Langeberg W, Danese M, Lindquist K, Gleeson M, Griffiths R, O’Malley C. Prevalence and Incidence of Colorectal
Cancer Comorbidities. American College of Epidemiology, 2010. San Francisco, USA.
Chia VM, Danese M, Lindquist K, Gleeson M, Griffiths R, O’Malley CD. Comorbid Conditions among Lung Cancer
Patients. American College of Epidemiology, 2010. San Francisco, USA.
Cetin K, Danese M, Lindquist K, Gleeson M, Griffiths R, O’Malley C. Comorbidities in Elderly Men with and
without Prostate Cancer (PC). American College of Epidemiology, 2010. San Francisco, USA.
Griffiths RI, Barron R, Lyman G, Gleeson M, Legg J, Chia V, O’Hagan A, Danese MD. Impact of GranulocyteColony Stimulating Factor (G-CSF) Use on Medical Costs after Initial Chemotherapy in Early Stage Breast Cancer.
San Antonio Breast Cancer Conference, 2010. San Antonio, USA.
Griffiths RI, Newsome BB, Block GA, Leung G, Danese MD. Impact of Hemodialysis Catheter Dysfunction on
Utilization of Medical Services. American Society of Nephrology, 2010. Denver, USA.
Griffiths RI, Newsome BB, Block GA, Leung G, Danese MD. Burden of Catheter Dysfunction in End-Stage Renal
Disease (ESRD). American Society of Nephrology, 2010. Denver, USA.
Danese MD, Griffiths RI, Gleeson M, Satram-Hoang S, Knopf K, Mikhael J, Reyes C. Survival Outcomes After
Initial Infused Therapy for Elderly Chronic Lymphocytic Leukemia (CLL) Patients. American Society of Clinical
Oncology, 2010. Chicago, USA.
10
Griffiths RI, Lindquist K, Lalla D, Doan J, Brammer M, Danese MD. Impact of CNS Metastases on Treatment and
Survival in Elderly Patients Receiving Trastuzumab for Metastatic Breast Cancer (MBC). American Society of
Clinical Oncology, 2010. Chicago, USA.
Doan J, Griffiths RI, Lalla D, Brammer M, Danese MD. Cost of Care for Medicare Patients Diagnosed with
Metastatic Breast Cancer Who received Trastuzumab. International Society for Pharmacoeconomics and
Outcomes Research, 2009. Orlando, USA.
Griffiths R, Lalla D, Brammer M, Herbert R, Doan J, Danese M. Trastuzumab Use and CNS Metastasis in
Medicare Patients Diagnosed with Metastatic Breast Cancer. American Society of Clinical Oncology, 2009.
Orlando, USA.
Danese M, O’Malley C, Lindquist K, Gleeson M, Griffiths R, Wyszwynski D. Comorbidity in Medicare Patients
With and Without Breast Cancer. American Society of Clinical Oncology, 2009. Orlando, USA.
O’Malley CD, Danese MD, Lindquist K, Griffiths RI, Gleeson M, Einhorn T, Wyszynski DF. Diabetes in Elderly
Patients with Breast Cancer in the United States: An Analysis of Data from the Surveillance, Epidemiology, and
End Results (SEER)-Medicare Linked Database. American Society of Clinical Oncology, 2009. Orlando, USA.
Danese M, Griffiths R, Gleeson M, Knopf K. Validating the Follicular Lymphoma International Prognostic Index
(FLIPI) Using SEER-Medicare Claims Data. Blood (ASH Annual Meeting Abstracts), 2008. 112: Abstract 872.
Mark Danese, Michelle Gleeson, Carolina Reyes, Mary Pao, Robert Griffiths, Kevin Knopf. Survival Patterns
Among Follicular Lymphoma Patients in SEER-Medicare. 10th International Conference on Malignant Lymphoma
June 4-7, 2008: Lugano, Switzerland.
Li Y, Friedman JY , O’Neal B, Griffiths RI, Stryjewski ME Schulman KA, Szczech L, Fowler VG., Reed SD. Inpatient
Costs and Clinical Outcomes of S. aureus Bloodstream and Non-bloodstream Infection in Patients with End-Stage
Renal Disease: Findings from a Multi-Center Trial. Poster Presentation at 2008 ISPOR 13th Annual International
Meeting , Abstract published in Value in Health, 2008; 11(3): A304. Toronto, Canada.
Griffiths R, Danese M, Gleeson M, Knopf K. Patterns of Chemotherapy/Immunotherapy and Survival in Mantle
Cell Lymphoma: Evidence from SEER-Medicare. Blood (ASH Annual Meeting Abstracts), 2008. 112: Abstract
5293.
Lau H, Duff S, Gricar J, Reyes E, Sung J, Davis P, Griffiths R. Cost-effectiveness of Aliskiren, a Direct Renin
Inhibitor, Compared with Current Antihypertensive Medications for Patients with Mild-to-Moderate
Hypertension. Journal of Managed Care Pharmacy, 2007;13(8):693.
Lalani T, Chu VH, Friedman JY, Reed SD, Griffiths RI, Crosslin DR, Masselink LE, Kaye KS, Kanafani ZA, Corey GR,
Fowler VG, Jr. Clinical Characteristics and Outcomes of Patients with Staphylococcus aureus Bacteremia and
Orthopedic Device Infections. Infectious Diseases Society of America 45th Annual Meeting, San Diego, USA.
October 2007.
Doan QV, Dylan M, Griffiths R, Borker R, Barber B, Kim J, Dubois RW. Economic Impact of Cardiovascular Disease
and Fractures in Patients with ESRD. National Kidney Foundation, 2007. April 10-14. Orlando, FL.
11
Robert Griffiths, Mark Danese, Brad Stolshek, and Glenn Chertow. Economic and Survival Benefits of Meeting
NKF-K/DOQI Bone Metabolism and Disease Targets. American Society of Nephrology, Renal Week, 2005.
November 8-13. Philadelphia, PA. (Proceedings).
Mark Danese, Robert Griffiths, Zhimei Liu, Michele Dylan, Robert Dubois, Hsing-Ting Yu, and Allen Nissenson.
Most Fistula and Graft Patients Are Exposed to Catheters. American Society of Nephrology, Renal Week, 2005.
November 8-13. Philadelphia, PA.
R. Griffiths, M. Dylan, R. Dubois, H-T Yu, and A Nissenson. Sepsis Increases Erythropoietin (EPO) Use and
Decreases Hematocrit (Hct) in Hospitalized End-Stage Renal Disease (ESRD) Patients. American Society of
Nephrology, Renal Week, 2005. November 8-13. Philadelphia, PA.
Danese M, Griffiths RI, Dylan M, Yu H-T, Dubois R, Nissenson A. Mortality Differences Among Organisms Causing
Septicemia in Hemodialysis Patients. European Renal Association-European Dialysis and Transplant Association,
XLII Congress, 2005. June 5-8. Istanbul Turkey.
Allen Nissenson, Zhimei Liu, Robert W. Dubois, Michelle Dylan, Hsing-Ting Yu, Mark Danese and Robert I.
Griffiths. Most Patients with Fistulas (AVFS) and/or Grafts (AVGS) Require a Catheter During Their Time on
Hemodialysis. European Renal Association-European Dialysis and Transplant Association, XLII Congress, 2005.
June 5-8. Istanbul Turkey.
Chu VH, Friedman JY, Reed SD, Levin LS, Griffiths RI, Crosslin DR, Masselink LE, Kanafani ZA, Kaye KS, Corey GR,
Fowler VG. Clinical Outcomes and Costs Due to Staphylococcus aureus Bacteremia Among Patients with
Orthopedic Devices. 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Los
Angeles, CA 2005.
Dylan M, Kim J, Klassen P, Doan QV, Griffiths R, Danese M. Association Between Serum Calcium and Risk of
Heart Valve Repair or Replacement in Hemodialysis Patients. American Society of Nephrology, Renal Week,
2004. October 27 – November 1, 2004. Saint Louis, MO, USA.
Dylan M, Kim J, Doan QV, Griffiths R, Danese M. Inpatient Costs of Acute Clinical Events Associated with
Secondary HPT in Hemodialysis Patients. American Society of Nephrology, Renal Week, 2004. October 27 –
November 1, 2004. Saint Louis, MO, USA.
Danese M, Dylan M, Dubois R, Yu H-T, Griffiths R, Nissenson A. Mortality in Hemodialysis Patients Hospitalized
with Septicemia Caused by S.aureus Compared to Other Organisms. American Society of Nephrology, Renal
Week, 2004. October 27 – November 1, 2004. Saint Louis, MO, USA.
Griffiths R, Dylan M, Dubois R, Yu H-T, Danese M, Nissenson A. Economic and Clinical Outcomes of
Hospitalization with S. aureus Septicemia in End-Stage Renal Disease Patients Receiving Hemodialysis. American
Society of Nephrology, Renal Week, 2004. October 27 – November 1, 2004. Saint Louis, MO, USA.
Chu VH, Cabell CH, Friedman JY, Reed SD, Griffiths RI, Kaye RS, Crosslin DR, Masselink LE, Stryjewski ME, Reller
LB, Schulman KA, Corey GR, Fowler, Jr VG. The Clinical and Economic Impact of Staphylococcus aureus
Bacteremia in Patients with Cardiac Devices. American Heart Association, Scientific Sessions 2004. November 7
– 10, 2004. New Orleans, LA, USA.
12
Chu VH, Friedman JY, Reed SD, Cabell SH, Griffiths RI, Kaye KS, Crosslin DR, Masselink LE, Stryjewski ME, Reller
LB, Schulman KA, Corey GR, Fowler, Jr VG. Staphylococcus aureus Bacteremia In Patients with Prosthetic Devices:
Costs and Outcomes. 44th Annual ICAAC. October 30 – November 2, 2004. Washington DC, USA.
Tandon N, McGowen J, Nagle P, Griffiths R. Recent Economic Analysis of Etanercept Versus Infliximab: What
Can We Reasonably Conclude About Modeled Cost Differences Between the Two? EULAR. Berlin, Germany.
June 9-12, 2004.
Kim J, Dylan M, Doan Q, Griffiths R, Stehman-Breen C, Dubois R, Danese M. Association of Elevated Serum
Parathyroid Hormone (PTH) and Calcium with Risk of Hip, Vertebral or Pelvic Fracture in Hemodialysis Patients.
European Renal Association-European Dialysis and Transplant Association, XLI Congress, May 15-18 2004, Lisbon
Portugal.
Stovsky MD, Laskin CR, Griffiths RI. A Clinical Outcomes and Cost Analysis Comparing Photoselective
Vaporization of the Prostate to Alternative Minimally Invasive Therapies & TURP for the Treatment of Benign
Prostatic Hyperplasia. American Urological Association Annual Meeting 2004. San Francisco, CA. May 8-13,
2004.
Chu VH, Friedman JY, Reed SD, Levin LS, Griffiths RI, Crosslin DR, Masslink LE, Kaye KS, Stryjewski ME, Reller LB,
Schulman KA, Corey GR, Fowler Jr VG. Clinical Outcomes and Costs Due to Staphylococcus aureus Bacteremia
Among Patients with Orthopedic Devices. Society for Hospital Epidemiologists of America. April 9-12, 2004.
Reed SD, Szczech LA, Kaye KS, Friedman JY, Engemann JJ, Stryjewski ME, Griffiths RI, Reller LB, Corey GR, Fowler
VG. Methicillin-Resistant Staphylococcus aureus Leads to Higher Inpatient Costs, Longer Hospital Stays, and
Higher Mortality in End-Stage Renal Disease Patients on Hemodialysis. 43rd Annual ICAAC. September 14-17,
2003. Chicago IL, USA.
Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, Stryjewski ME, Reller LB, Corey GR, Fowler
VG. Clinical Outcomes and Economic Costs Due to S. aureus Bacteremia (SAB) Among Hemodialysis-Dependent
(HD) Patients. 43rd Annual ICAAC. September 14-17, 2003. Chicago IL, USA.
Griffiths RI, Young GP, Mandel JS, Cromwell DM, Rabeneck L. Cost-Effectiveness of Colorectal Cancer Screening
with an Immunochemical Fecal Occult Blood Test (FOBT) Versus Guaiac FOBT. 68th Annual Meeting of the
American College of Gastroenterology. October 10-15, 2003. Baltimore MD, USA.
Griffiths RI, Bar-Din M, MacLean C, Sullivan E, Herbert R, Yelin E. Medical Resource Use and Costs Among
Rheumatoid Arthritis (RA) Patients Receiving Disease Modifying Antirheumatic Drug (DMARD) Therapy in the
United States. 16th Annual Meeting of the International Society of Technology Assessment in Health Care. June
18-21, 2000. The Hague, The Netherlands.
Griffiths RI, Duff S, Prosek B, Llana T. Simulated Lifetime Costs to the National Health Service (NHS) of Biological
and Mechanical Heart Valve Replacement in Younger Versus Older Patients. International Society for
Pharmacoeconomics and Outcomes Research Second Annual European Conference. November 10-13, 1999.
Edinburgh, Scotland.
Griffiths RI, Wargo MC, Friedman M. Medical Resource Use and Payer Costs of Inpatient and Outpatient Care
Related to Epilepsy. International Society for Pharmacoeconomics and Outcomes Research. Fourth Annual
Meeting. May 23-26, 1999. Arlington, VA.
13
Griffiths RI, Bar-Din M, Yelin E, Herbert RJ, Sullivan EM, Slurzberg JEF, MacLean C. Pharmacoepidemiology of
Initial Disease Modifying Antirheumatic Drug (DMARD) Therapy in a Managed Care Organization (MCO).
International Society for Pharmacoeconomics and Outcomes Research. Fourth Annual Meeting. May 23-26,
1999. Arlington, VA.
Griffiths RI, Schrammel PN, Morris GL, Wills SH, Labiner DM, Strauss MJ. Payer Costs of Patients Diagnosed with
Epilepsy. American Epilepsy Society 52nd Annual Meeting. December 4-10, 1998. San Diego, CA.
Sullivan EM, Griffiths RI. Economic Outcomes of Selective Serotonin Reuptake Inhibitor (SSRI) Versus Tricyclic
Antidepressant (TCA) Therapy Among Patients Enrolled in a Managed Care Organization. American Public
Health Association 126th Annual Meeting. November 17, 1998. Washington, DC.
Sullivan EM, Griffiths RI, Frank RG, Herbert RJ, Strauss MJ, Goldman HH. One-Year Costs of Alternative Secondline Therapies for Depression. 50th Institute on Psychiatric Services. October 2-6, 1998. Los Angeles, CA.
Goss TF, Griffiths RI, Fekete T, Meyer RD, Paladino JA, Zervos M, Gill DS. A Decision Model to Evaluate the Costs
and Outcomes of Alternative Treatments for Enterococcus faecium Bloodstream Infections. Interscience
Conference on Antimicrobial and Chemotherapeutic Agents. September 25, 1998. San Diego, CA.
Griffiths RI, Rabeneck L, Guzman G, Cromwell DM, Strauss MJ, Robinson JW, Winston B, Li T, Graham DY.
Pharmacoeconomic Evaluation of Alternative Approaches to Managing H. Pylori-infected Ulcer Patients
Following Initial Therapy. International Society of Technology Assessment in Health Care. 14th Annual Meeting.
June 7-10, 1998. Ottawa, Ontario, Canada.
Sullivan EM, Griffiths RI, Frank RG, Herbert RJ, Strauss MJ, Goldman HH. One-Year Costs of Alternative Secondline Therapies for Depression. American Psychiatric Association 1998 Annual Meeting. May 30-June 4, 1998.
Toronto, Ontario, Canada.
Griffiths RI, Sullivan EM, Frank RG, Herbert RJ, Strauss MJ, Goldman HH. Medical Costs of Effexor® versus
Tricyclic or Tetracyclic Antidepressant Therapy after Switching from Selective Serotonin Reuptake Inhibitors.
International Society for Pharmacoeconomics and Outcomes Research. Third Annual Meeting. May 27-30,
1998. Philadelphia, PA.
Griffiths RI, Hyman CL. Medical Decision Making for Suspected Tuberculosis During Hospitalization: Impact of
Diagnostic Uncertainty on Resource Use. 19th Annual Meeting of the Society for Medical Decision Making.
October 26-29, 1997. Charlotte, NC.
O’Brien T, Griffiths RI, Eisenberg P, Popper C, Robinson J. Impact of Point of Care STAT CBC on Turnaround Time
for Test Results and Duration of Visit in a Managed Care Outpatient Center: Evidence from a randomized,
controlled trial. International Society for Technology Assessment in Health Care (ISTAHC). ISTAHC 12th Annual
Meeting. June 1996. San Francisco, CA.
Steinberg EP, Griffiths RI, Bleecker GC. Costs and Outcomes of Alternative Approaches to Treating
Cytomegalovirus (CMV) Retinitis in Persons with AIDS (PWA). Investigative Ophthalmology & Visual Science
1996;37(3):S899.
14
Griffiths RI, O’Brien T, Eisenberg P, Popper C, Robinson J. Impact of Point of Care STAT CBC on Turnaround Time
for Test Results and Duration of Visit in a Managed Care Outpatient Center: Evidence from a randomized,
controlled trial. American Society of Clinical Pathologists 1996.
Fleurette-David FM, Bass EB, Griffiths RI, Powe NR, Anderson GF, Wingard JR. Cost-Effectiveness of Prophylactic
Use of Immune Globulin in Bone Marrow Transplant Patients. International Society for Technology in Health
Care (ISTAHC). June 1994.
Powe NR, Watson AJ, Griffiths RI, Greer J, Whelton PK. Dosing, Response to, and Effectiveness of Erythropoietin
(EPO) in End Stage Renal Disease. J Clin Pharmacol 1992;12(4):349.
Powe NR, Griffiths RI, Watson AJ, de Lissovoy G, Anderson GF, Herbert RJ, Greer J, Whelton PK. Impact of
Erythropoietin (EPO) on All-Cause and Cause-Specific Hospitalization. J Am Soc Nephrol 1992;3(3):430.
Griffiths RI, Powe NR, de Lissovoy G, Anderson GF, Watson AJ, Herbert RJ, Greer J, Whelton PK. Access to
Erythropoietin (EPO) in the First Two Years After FDA Approval and Medicare Coverage. J Am Soc Nephrol
1992;3(3):426.
Bass EB, Bergner M, Pitt HA, Lillemoe KD, Saba GP, Griffiths RI, Johns C, Steinberg EP. Comparison of Patient
Utilities for Gallstone Treatments and Related Outcomes by Rating Scale and Standard Gamble Techniques.
Society for Medical Decision Making 1991.
Bass E, Powe NR, Graziano SL, Goodman SN, Griffiths RI, Kickler TS, Wingard JR. Efficacy of Prophylactic
Intravenous Immune Globulin in Bone Marrow Transplantation: A Meta Analysis. In: Program and Abstracts of
the 31st Interscience Conference of Antimicrobial Agents and Chemotherapy (Chicago), Washington, DC:
American Society for Microbiology 1991.
de Lissovoy G, Powe NR, Griffiths RI, Anderson GF, Greer J, Herbert RJ, Watson AJ, Milam R, Eggers P, Whelton
PK. Role of Provider Characteristics in Erythropoietin Administration to Hemodialysis Patients. J Am Soc Nephrol
1991;2(3):386.
Powe NR, de Lissovoy G, Griffiths RI, Anderson GF, Watson AJ, Herbert RJ, Greer J, Milam R, Eggers P, Whelton
PK. National Study of Patient Factors and Costs Associated with Use of Recombinant Erythropoietin in ESRD
During First Year of HCFA Funding. J Am Soc Nephrol 1991;2(3):386.
de Lissovoy G, Powe NR, Griffiths RI, Anderson GF, Whelton PK, Watson AJ. Using Claims Data for Outcome
Analysis: The Case of Erythropoietin Therapy. (Abstract 120) Proceedings of the 7th Annual Meeting of the
International Society for Technology Assessment in Health Care 1991. Helsinki, Finland.
Powe NR, de Lissovoy G, Griffiths RI, Anderson GF, Herbert RJ, Watson AJ, Whelton, PK. Early Diffusion of
Recombinant Erythropoietin in the End Stage Renal Disease Population. Clinical Research 1991;39:372A.
Powe NR, Griffiths RI, Bass EB. Cost Implications of Recombinant Erythropoietin for Anemia of End Stage Renal
Disease. Clinical Research 1991;39:607A.
Powe NR, Griffiths RI, Watson AJ, de Lissovoy G, Anderson GF, Herbert RJ, Greer J, Milam R, Eggers P, Whelton
PK. National Study of Erythropoietin Dosing and Effectiveness in Increasing Hematocrit for ESRD Patients. J Am
Soc Nephrol 1991;2(3): 386.
15
Powe NR, Griffiths RI, Whelton P, Watson A, Anderson GF, Herbert RJ, Greer J, Milam R, Eggers P. Short-Term
Survival Associated with Use of Recombinant Erythropoietin in ESRD Patients. J Am Soc Nephrol 1991;2(3):386.
16
Editorial Board and Peer-Review
2013 →
Reviewer, Cancer Research UK Population Research Committee
2013 →
Associate Editor, BMC Endocrine Disorders
1993 →
Reviewer (select journals)
Journal of Clinical Oncology
Cancer Investigation
Clinical Therapeutics
Value in Health
Pharmacoeconomics
17